Gout Therapeutics Market to Reach $2,683.1 Million in 2035, Growing at 6.1% CAGR

Gout therapeutics market valued at $1,645.2 million in 2025 and is projected to reach $2,683.1 million by 2035, growing at a CAGR of 5.0% during the forecast period (2026-2035). The market includes pharmacological treatments aimed at managing uric acid levels and relieving inflammation associated with gout. The market is experiencing steady global growth driven by the increasing prevalence of hyperuricemia, rising incidence of lifestyle-related disorders, and growing awareness regarding early diagnosis and treatment of gout. Expansion is further supported by aging populations, increasing obesity rates, and dietary patterns associated with high purine intake. Pharmaceutical companies are focusing on developing advanced urate-lowering therapies, combination drugs, and biologics to improve patient outcomes. Additionally, improved access to healthcare services and the availability of generic medications are contributing to wider treatment adoption across emerging economies. According to global health organizations and epidemiological data, the rising burden of metabolic disorders and chronic conditions is significantly contributing to the increasing incidence of gout worldwide. Large-scale population health datasets and disease surveillance systems are enabling better estimation of patient populations, treatment utilization patterns, and long-term therapeutic demand across regions.

Browse the full report description of “Gout Therapeutics Market Size, Share & Trends Analysis Report by Drug Class (Antihyperuricemic Agents, Non-Steroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Colchicine and Others), By Application (Acute Gout and Chronic Gout) Forecast Period, (2026-2035)” at https://www.omrglobal.com/industry-reports/gout-therapeutics-market

Key Statistics: Gout Therapeutics at a Glance

• Gout affects over 55 million people globally, making it one of the most common forms of inflammatory arthritis.
• Prevalence of gout ranges between 1% to 4% of the global adult population, with higher rates observed in developed economies.
• Hyperuricemia, the primary risk factor for gout, affects nearly 20% of adults worldwide, driving sustained demand for urate-lowering therapies.

Key Innovators Driving Gout Therapeutics Transformation

The key players in the gout therapeutics market include BASF SE, F. Hoffmann-La Roche Ltd., Merck KGaA, Novozymes A/S, Thermo Fisher Scientific Inc, among others.

• In June 2025, Horizon Therapeutics reinforced its focus on chronic gout management by expanding patient access initiatives and advancing lifecycle strategies for its biologic therapies targeting refractory gout.
• In April 2025, Takeda Pharmaceutical Company reported progress in its metabolic disorder pipeline, highlighting investigational approaches designed to enhance long-term uric acid control and reduce complications associated with gout.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Drug Class
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - BASF SE, F. Hoffmann-La Roche Ltd., Merck KGaA, Novozymes A/S, Thermo Fisher Scientific Inc, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Gout Therapeutics Market Report Segment

By Drug Class

• Antihyperuricemic Agents
• Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
• Corticosteroids
• Colchicine
• Others

By Application

• Acute Gout
• Chronic Gout

Global Gout Therapeutics Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/gout-therapeutics-market